Helixgate

Helixgate

Uncategorized

Vertex presents new data on Casgevy in children

Published

on

Sickle cells

Vertex Pharmaceuticals has announced data demonstrating the clinical benefits of Casgevy (exagamglogene autotemcel) in people ages five years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT).  

The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with those established in adult and adolescent patients.  

The data were presented at the European Hematology Association (EHA) Congress and simultaneously published in the New England Journal of Medicine (NEJM). 

“The data presented at EHA and published in NEJM underscore the consistent, durable and transformative benefits Casgevy can provide to people living with sickle cell disease or transfusion-dependent beta thalassemia from early in life,” said Dr Carmen Bozic, Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. 

Franco Locatelli, Professor of Pediatrics at the Catholic University of the Sacred Heart of Rome, and Director of the Department of Pediatric Hematology and Oncology at Bambino Gesù Children’s Hospital, added: “These data represent a profoundly important step forward, and I look forward to the possibility of providing earlier intervention to prevent complications in children and for families who have had limited potentially curative options to date.” 

Casgevy is currently approved for eligible people 12 years and older with SCD with recurrent VOCs or TDT in several countries around the world. In the US the regulatory review is underway with the FDA to expand the use of Casgevy to younger children after Vertex was awarded the Commissioner’s National Priority Voucher.  

Vertex has also recently completed regulatory submissions in the Kingdom of Saudi Arabia and UK to expand the use of Casgevy to younger children.

The post Vertex presents new data on Casgevy in children appeared first on Drug Discovery World (DDW).

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

STAT+: DOJ’s swift win in OhioHealth case should have hospitals studying their contracts, experts say

Legal experts say the speed and decisiveness of the Department of Justice’s proposed antitrust settlement with OhioHealth should put other hospitals on notice. 

The DOJ and Ohio Attorney General’s proposed settlement announced Wednesday would require nonprofit OhioHealth to quit using certain contracting practices that the agencies say prevented health insurers from selling cheaper policies. The deal, which comes just four months after the agencies sued the Columbus-based system, will likely push other health systems to examine their own contracting practices. 

“I would expect lawyers will get pretty busy looking at contracts with payers,” said Katie Keith, the director of Georgetown University’s Center for Health Policy and the Law. 

Continue to STAT+ to read the full story…

Read More

Published

on

Legal experts say the speed and decisiveness of the Department of Justice’s proposed antitrust settlement with OhioHealth should put other hospitals on notice. 

The DOJ and Ohio Attorney General’s proposed settlement announced Wednesday would require nonprofit OhioHealth to quit using certain contracting practices that the agencies say prevented health insurers from selling cheaper policies. The deal, which comes just four months after the agencies sued the Columbus-based system, will likely push other health systems to examine their own contracting practices. 

“I would expect lawyers will get pretty busy looking at contracts with payers,” said Katie Keith, the director of Georgetown University’s Center for Health Policy and the Law. 

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

Personalized Cartilage Graft Developed for Life-Threatening Infant Airway Narrowing

Published

on

A study led by researchers at Children’s Hospital of Philadelphia (CHOP) demonstrated a new method of using decellularized cartilage with patient-specific cells to help enlarge the pediatric airways narrowed as a result of severe subglottic stenosis (SGS). The condition is a narrowing of the airway below the vocal cords and above the trachea, and affects an estimated 20,000 infants per year.

Researchers demonstrated in a preclinical model that this new method of airway reconstruction was faster, more effective, and able to overcome issues, such as donor site morbidity, insufficient tissue volume and delayed timeline, associated with the current standard grafts used for laryngotracheal reconstruction (LTR).

Riccardo Gottardi, PhD, assistant professor with the Perelman School of Medicine at the University of Pennsylvania and leader of the Bioengineering and Biomaterials (Bio2) lab, and Ian Jacobs, MD, medical director of the Center for Pediatric Airway Disorders in the Division of Otolaryngology (ENT) at CHOP, co-led the research, which is reported in Nature Communications, in a paper titled “A translational approach to airway reconstruction leveraging decellularized meniscus and cartilage progenitor cells.” In their paper the team said, “This technology has the potential to revolutionize the field of pediatric LTR.”

Severe subglottic stenosis (SGS) develops in children almost exclusively as a response to intubation, and affects nearly 1.5% of the over 200,000 infants in intensive care units each year in the United States, the authors explained. The most severe cases require laryngotracheal reconstruction (LTR), an open airway surgery that is used to enlarge the airway by implanting cartilage taken from a rib cage. While LTR is used to successfully treat thousands of children with subglottic stenosis, in many cases, young children often lack enough costal cartilage—the cartilage connecting our ribs to the sternum—for these grafts.

As a result, operations often need to be delayed, leaving the child attached to a tracheostomy tube until they are older and grown enough to supply sufficiently sized cartilage for an effective LTR, and there is a higher risk of needing follow-up surgery because the airway is at risk of narrowing again. “In adults, LTR has a 90% success rate with low rates of revision,” the team stated. “However, in children, success rates significantly drop, and the incidence of restenosis requiring revision surgery increases to over 24%.”

To improve this process and reduce the risk of these potential complications, Gottardi and Jacobs and colleagues have been looking at tissue engineering a laryngotracheal graft. Tissue engineering, the team wrote, could provide “an ideal alternative to autologous cartilage grafts to alleviate unnecessary comorbidities as well as reduce surgical time.” However, the complexity of the trachea prevents the use of conventional cartilage engineering techniques for this procedure.

“We needed something that could be equivalent to a piece of cartilage, integrate well with the surrounding tissue, be well tolerated by the patient, behave like native tissues and regrow and be part of the airway,” Gottardi said. “This required quite a bit of creative thinking because of the additional challenges in children who are so small and still growing.”

To overcome the limitations of existing methods, the researchers, led by former Gottardi lab member Paul Gehret, PhD, created a first-of-its-kind scaffold based on porcine meniscal cartilage decellularization (MEND – MENiscus Decellularization). They realized that if the cells, elastin, and blood vessels present in the meniscus are “digested” away, the meniscal cartilage becomes amenable to recellularization and integration while being less likely to provoke an immune response. In their paper the researchers explained, “Building on the strengths of previous decellularized therapies, we established an innovative approach that leverages the selective enzymatic removal of the elastin fibers and blood vessels uniquely present in the fibro-elastic cartilage of the meniscus to create microchannels, which support cellular invasion while substantially preserving native structure.”

Using ear-derived cartilage progenitor cells (eCPCs), which can mature into cartilage-producing chondrocytes, the researchers demonstrated that MEND can be recellularized after the removal of elastin and blood vessels and suitable for implantation in less than a month. “Notably, porcine menisci, such as those used in this study, are a highly abundant cartilage source, being easily available as a waste product of the food industry, which can ensure no shortage of material for surgeons to shape into an ideal implant,” the team noted.

Importantly, the new method needed to work in a clinically relevant timeframe. In a real-world scenario, clinicians may only have one or two months to be able to perform the procedure when it can still benefit the patient. Harvesting seed cells within days and creating a scaffold within three to four weeks is significantly less time than the six months that was typically needed for engineered cartilage. “Here we demonstrate that MEND can be fully recellularized in three days with ear-derived cartilage progenitor cells and reaches structural and functional maturation suitable for implant within three weeks of chondrogenic differentiation, a time frame compatible with clinical translation,” the authors stated.

They validated their technology in a preclinical rabbit in vivo model, and demonstrated better performance than costal cartilage, the standard of care, with no instances of adverse events reported. “Our results demonstrate airway expansion, graft reepithelialization, neocartilage formation, and integration with adjacent native laryngotracheal cartilage at three months,” the team stated. “Notably, MEND implants perform better in all outcomes than autologous costal cartilage, the standard of care.”

These findings will be further validated prior to proposing the procedure for patients suffering from severe subglottic stenosis. “These results demonstrate the feasibility of our translational tissue engineering approach to laryngotracheal reconstruction and could overcome the autograft-associated limitations in pediatric patients, decreasing the need for invasive revision surgery,” the investigators concluded.

“This research shows really promising data that suggests this novel approach could overcome the autograft-associated limitations we sometimes encounter when attempting laryngotracheal reconstruction in infants,” Jacobs said. “With more research, we expect this could decrease the need for invasive surgery, and we may be able to apply the technology to other conditions that require a cartilage graft.”

The post Personalized Cartilage Graft Developed for Life-Threatening Infant Airway Narrowing appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Uncategorized

FTC, four state AGs sue transgender health group over care standards

The Federal Trade Commission and four state attorneys general have sued the main professional organization for gender-affirming care clinicians, alleging it made false claims to sell medical services to kids.

The lawsuit against the World Professional Association for Transgender Health, filed Wednesday in a federal court in Texas, is part of the Trump administration’s broader effort to end gender-affirming care for minors. 

Read the rest…

Read More

Published

on

The Federal Trade Commission and four state attorneys general have sued the main professional organization for gender-affirming care clinicians, alleging it made false claims to sell medical services to kids.

The lawsuit against the World Professional Association for Transgender Health, filed Wednesday in a federal court in Texas, is part of the Trump administration’s broader effort to end gender-affirming care for minors. 

Read the rest…

Read More

Continue Reading
Advertisement

Trending